ACAntonella Campanale

Antonella Campanale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonella Campanale has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Achille Iachino

    Directorate General of Medical Devices and Pharmaceutical service of the Italian Ministry of Health, Rome, Italy

    4 shared publications
  • Marco Ventimiglia

    3 shared publications
  • Lucia Lispi

    Directorate General of Medical Devices and Pharmaceutical service, Italian Ministry of Health, Rome, Italy

    2 shared publications
  • Marcella Marletta

    From the Directorate General of Medical Devices and Pharmaceutical Services, Medical Device Vigilance System and Inspections, and the Directorate General of Digitalization, Health Informative System and Statistics, Italian Ministry of Health; and the Department of Public Health and Infectious Diseases, Sapienza University of Rome

    2 shared publications
  • Marco Alfò

    Department of Statistical Sciences, Sapienza University of Rome, Rome, Italy

    2 shared publications
  • Rosaria Boldrini

    General Directorate of Medical Devices and Pharmaceutical Services, Medical Device Vigilance System and Inspections, Italian Ministry of Health, Rome, Italy

    2 shared publications

Latest Publications

  • Open Access

    Toward Successful International Pooling of Breast Implant Registry Data: The Role of Dataset Uniformity

    by Uwe Von Fritschen, Iris Moes, Susannah Ahern, Patrick Garduce, Puck Melse, Marco Ventimiglia, Hinne Rakhorst, Marc A M Mureau, Martin Halle, Antonella Campanale, et al.

    Background: Despite widespread clinical use, the long-term performance of breast implants remains debated. Current evidence is limited by small sample sizes and inconsistent methodologies. National breast device registries provide valuable real-world data, yet their impact is constrained by heterogeneity in variable definitions, data structures, and analytical approaches. The International Collaboration of Breast Registry Activities (ICOBRA) initiative established a harmonized dataset utilized by several countries. Objectives: Evaluate the implementation of the dataset of the ICOBRA across national registries, identify inconsistencies in data definitions and structures, and develop an updated international dataset supporting standardized, federated analyses. Methods: Datasets from 5 national breast implant registries utilizing the harmonized dataset were systematically reviewed. Variations in data points and definitions were identified and discussed through a series of in-person and online consensus meetings. Structured voting was used to finalize revisions and establish the updated international core dataset. Results: Key discrepancies were identified in the classification of surgical indications, inclusion of implant types, and variable definitions across registries. As a result, more than half of the original core variables required revision, reclassification, or removal to enable multinational analyses. A federated analysis model was proposed to accommodate privacy regulations and registry diversity while supporting standardized, risk-adjusted analyses. Conclusions: The updated international breast implant registry dataset represents a crucial step toward integrated global surveillance. Together with standardized statistical methods within a federated data model, it enables robust pooled analyses without requiring uniform registry structures. Countries are encouraged to adopt the revised dataset and contribute to a collaborative framework that enhances patient safety through structured, large-scale data collection and analysis. Level of Evidence: 5 (Therapeutic): For image description, please refer to the figure legend and surrounding text.


  • High-Quality, Safe, and Accessible Free Care for BIA-ALCL Patients Within the Italian Public Healthcare System

    by Antonella Campanale, Achille Iachino

    Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicin

  • The (In-)Ability to Effectively Critique a Method Undermines the Validity of the Criticism

    by Marco Alfò, Marco Ventimiglia, Antonella Campanale

    Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicin


  • Current Knowledge on Breast Implant-Associated Anaplastic Large Cell Lymphoma: Evidence from Italian Ministry of Health Registry Data

    by Antonella Campanale, Marco Ventimiglia, Marco Alfò, Marta Cipriani, Daniela Minella, Lucia Lispi, Achille Iachino

    Background Accurate estimation of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) incidence is crucial for assessing breast-implant-associated risk. However, the size of the implanted population worldwide is unknown, making it challenging to appropriately estimate this figure. This study aims to provide a new reliable and reproducible method to estimate the breast-implanted-population (BIP), reporting a reliable annual BIA-ALCL incidence estimate. Moreover, we discuss all activities performed over the past decade in collecting complete histories, managing, and monitoring outcomes of each Italian case. Methods Data from the National Breast Implant Registry and from manufacturers have been used to define a new formula to estimate the BIP at risk of developing a breast-implant-related event. From the BIA-ALCL registry, complete information on Italian cases has been collected and analysed. Overall survival is estimated by the Kaplan-Meier curve. Results From 2010 to June 2024, 111 BIA-ALCL cases were recorded in Italy. The estimated incidence rate showed an upward trend, ranging from 2.68 to 6.35 cases per 100,000 patient-years. Thanks to newly promoted disease awareness, most patients had a complete response to treatment, resulting in a three-year overall survival rate estimate of 98.2%. Conclusions The BIP formula showed to be an innovative, effective and reproducible tool to make a reliable estimation of the implanted population, confirming that BIA-ALCL is a rare disease with an incidence rate estimate varying from 2.7 to 6.3 cases/100.000 patient-years in the last five years. Eleven-year experience in this field also confirmed that this disease has a favorable prognosis if properly treated. Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.


  • Open Access

    Epidemiological and Molecular Investigation of the Heater–Cooler Unit (HCU)-Related Outbreak of Invasive Mycobacterium chimaera Infection Occurred in Italy

    by Angela Cannas, Antonella Campanale, Daniela Minella, Francesco Messina, Ornella Butera, Carla Nisii, Antonio Mazzarelli, Carla Fontana, Lucia Lispi, Francesco Maraglino, et al.

    Background: From 2013 onwards, a large outbreak of Mycobacterium chimaera (MC) invasive infection, which was correlated with the use of contaminated heater–cooler units (HCUs) during open chest surgery, was reported from all over the world. Here, we report the results of the epidemiological and molecular investigations conducted in Italy after the alarm raised about this epidemic event. Methods: MC strains isolated from patients or from HCU devices were characterized by genomic sequencing and molecular epidemiological analysis. Results: Through retrospective epidemiological analysis conducted between January 2010 and December 2022, 40 possible cases of patients infected with MC were identified. Thirty-six strains isolated from these patients were analysed by whole genome sequencing (WGS) and were found to belong to the genotypes 1.1 or 1.8, which are the genotypes correlated with the outbreak. Most of the cases presented with prosthetic valve endocarditis, vascular graft infection or disseminated infection. Among the cases found, there were 21 deaths. The same analysis was carried out on HCU devices. A total of 251 HCUs were found to be contaminated by MC; genotypes 1.1 or 1.8 were identified in 28 of those HCUs. Conclusions: To ensure patients’ safety and adequate follow-up, clinicians and general practitioners were made aware of the results and public health measures, and recommendations were issued to prevent further cases in the healthcare settings. The Italian Society of Cardiac Surgery performed a national survey to assess the incidence of HCU-related MC prosthetic infections in cardiac surgery. No cases were reported after HCU replacement or structural modification and disinfection and possibly safe allocation outside surgical rooms.


  • Acute coronary syndrome in women: a new and specific approach is needed

    by Federica Moscucci, Franco Lavalle, Cecilia Politi, Antonella Campanale, Giovanella Baggio, Susanna Sciomer

    Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity across Europe particularly in women. Indeed, 47% of women die for CVD compared with 39% of men.1,2 Similarly, women die more frequently than men during acute myocardial infarction (AMI).1,3 Moreover, the well-known improvement of chronic CVD prognosis that occurred in the past 10 years pertains mainly to the male gender. This is possibly linked to the greater adherence to guidelines and secondary prevention programmes reported in males compared with females.4 Several pieces of evidence confirm this gender-related differences in CVD outcome. First of all, AMI mortality is substantially reduced in both sexes.4 Regardless, significant differences persist in outcomes between men and women and specifically in AMI outcome of young female population5 and elderly women (aged >75 years).6 Indeed, De Luca et al.6 in a large retrospective data...


  • The Crucial Role of Surgical Treatment in BIA-ALCL Prognosis in Early- and Advanced-Stage Patients

    by Antonella Campanale, Alessandra Spagnoli, Lucia S.D. Lispi, Rosaria S.D. Boldrini, Marcella Marletta

    Background: Studies on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) are trying to optimize medical and surgical treatments for early and advanced stages of this disease. The aim of this article is to share the experience gathered on the authors’ prospectively collected 46 well-documented cases. Methods: Italian physicians are obliged to report BIA-ALCL cases to the Italian Ministry of Health. Because of this cooperation with health care professionals, the competent authority has coordinated and centralized the collection of information for each patient in 46 cases of BIA-ALCL. Statistical analyses with cumulative incidence and corresponding 95 percent confidence interval are provided for each year, dividing the number of new cases that occurred in a defined year and the population at risk of experiencing BIA-ALCL during the same year. Results: The mean time to the onset of symptoms is reduced to 6.4 ± 3.77 years (range, 1 to 22 years). Increased knowledge has also shortened the average time to diagnosis, at 7.2 ± 3.71 years (range, 2 to 22 years). A late seroma appears in 91 percent of cases. The patient who died underwent limited surgery. The Italian incidence has been estimated as 2.8 per 100,000 patients receiving implants (95 percent CI, 0.88 to 4.84) in 2015; 2.1 (95 percent CI, 0.43 to 3.86) in 2016; 3.2 (95 percent CI, 1.11 to 5.31) in 2017; and 3.5 (95 percent CI, 1.36 to 5.78) in 2018. Conclusion: Although the number of cases has risen slightly, BIA-ALCL is still a rare disease with a stable incidence, easily recognized and with a favorable prognosis also in advanced stages if complete surgical excision is performed.